Type 2 Diabetes

Metabolic Diseases
129
Pipeline Programs
30
Companies
50
Clinical Trials
2 recruiting
23
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
2
16
5
47
49
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2858%
Small Molecule
2042%
+ 122 programs with unclassified modality

On Market (23)

Approved therapies currently available

AstraZeneca
BYETTAApproved
exenatide
AstraZeneca
GLP-1 Receptor Agonist [EPC]subcutaneous2005
U
CANDESARTAN CILEXETILApproved
candesartan
Unknown Company
oral2016
U
EMPAGLIFLOZINApproved
empagliflozin
Unknown Company
oral
U
EXENATIDE SYNTHETICApproved
exenatide
Unknown Company
GLP-1 Receptor Agonist [EPC]subcutaneous2024
AstraZeneca
FARXIGAApproved
dapagliflozin
AstraZeneca
oral2014
Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
AstraZeneca
KOMBIGLYZE XRApproved
saxagliptin and metformin hydrochloride
AstraZeneca
oral2010
Sanofi
LANTUSApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
Sanofi
LANTUS SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
U
LIRAGLUTIDEApproved
liraglutide
Unknown Company
GLP-1 Receptor Agonist [EPC]subcutaneous2025
U
NORLIQVAApproved
amlodipine
Unknown Company
Dihydropyridine Calcium Channel Blocker [EPC]oral2022
AstraZeneca
ONGLYZAApproved
saxagliptin
AstraZeneca
oral2009
Novo Nordisk
OZEMPICApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2017
Novo Nordisk
RYBELSUSApproved
oral semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]oral2019
Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
Novartis
STARLIXApproved
nateglinide
Novartis
oral2000
Sanofi
TOUJEO MAX SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Sanofi
TOUJEO SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Boehringer Ingelheim
TRADJENTAApproved
linagliptin
Boehringer Ingelheim
Dipeptidyl Peptidase 4 Inhibitor [EPC]oral2011
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010
Novo Nordisk
WEGOVYApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]oral2025
U
WELCHOLApproved
colesevelam hydrochloride
Unknown Company
oral2000
AstraZeneca
XIGDUO XRApproved
dapagliflozin and metformin hydrochloride
AstraZeneca
oral2014

Competitive Landscape

35 companies ranked by most advanced pipeline stage

Novo Nordisk
36 programs
1
10
12
DegludecPhase 41 trial
Detemir + aspart insulin before mealsPhase 41 trial
Detemir or GlarginePhase 41 trial
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injectorPhase 4Peptide
LevemirPhase 41 trial
+31 more programs
Active Trials
NCT06111508Completed30Est. Sep 2024
NCT05948969Unknown750Est. Dec 2024
NCT07237685Recruiting1,000Est. Oct 2036
+32 more trials
AstraZeneca
27 programs
2
5
14
1
DapagliflozinPhase 3Small Molecule1 trial
DapagliflozinPhase 3Small Molecule1 trial
KOMBIGLYZE XR(Saxagliptin)Phase 3Small Molecule5 trials
ONGLYZA(Saxagliptin)Phase 3Small Molecule1 trial
TesaglitazarPhase 31 trial
+22 more programs
Active Trials
NCT03694470Completed10,000Est. Jun 2018
NCT00979394Terminated1,513Est. Jan 2010
NCT01944618Terminated5,000Est. Oct 2015
+38 more trials
DS
12 programs
3
2
4
3
AmlodipinePhase 4Small Molecule1 trial
ColesevelamPhase 41 trial
Intensive carePhase 41 trial
Colesevelam HClPhase 31 trial
Colesevelam hydrochloridePhase 31 trial
+7 more programs
Active Trials
NCT00147745Completed36Est. Jan 2008
NCT00575874Completed150Est. Jan 2009
NCT00575471Completed250Est. Mar 2008
+9 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
5 programs
3
EmpagliflozinPhase 4Small Molecule1 trial
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injectorPhase 4Peptide1 trial
LinagliptinPhase 4Small Molecule1 trial
EmpagliflozinN/ASmall Molecule1 trial
HOP watchN/A1 trial
Active Trials
NCT03050619Completed31,908Est. Oct 2016
NCT05482958Completed210Est. Sep 2025
NCT02637973Completed84Est. Aug 2018
+2 more trials
Sanofi
5 programs
1
1
1
LIXISENATIDEPhase 2Peptide5 trials
insulin glargine + exenatide + preexisting metforminPhase 1Peptide1 trial
ExenatideN/APeptide1 trial
Nurse Case ManagementN/A1 trial
The Impact of Food on Blood Sugar in People With Type 2 DiabetesN/A1 trial
Active Trials
NCT01089569Completed60Est. May 2013
NCT01659294Completed140Est. Feb 2015
NCT01237314Completed46Est. May 2013
+6 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
5 programs
3
2
Lispro mix 75/25Phase 41 trial
exenatidePhase 4Peptide3 trials
Insulin Efsitora AlfaPhase 31 trial
exenatidePhase 3Peptide1 trial
exenatidePhase 3Peptide1 trial
Active Trials
NCT05275400Completed986Est. May 2024
NCT00577824Completed181Est. Nov 2008
NCT00753896Completed134Est. Nov 2009
+4 more trials
Novartis
NovartisBASEL, Switzerland
3 programs
2
NateglinidePhase 41 trial
Vildagliptin/ MetforminPhase 41 trial
GlimepirideN/A
Active Trials
NCT00402909Completed28Est. Aug 2007
NCT01518101Completed62Est. Oct 2012
Bayer
3 programs
2
Insulin GlarginePhase 4
weekly blood glucose profilePhase 41 trial
Glucobay MN/A1 trial
Active Trials
NCT01219582Completed9,364Est. Dec 2012
NCT00688363Completed300Est. Dec 2008
Celltrion
CelltrionKorea - Incheon
2 programs
1
Pioglitazone 15 MG [Actos]Phase 41 trial
Dual-combination therapyN/A1 trial
Active Trials
NCT06627322RecruitingEst. Sep 2029
NCT06989723RecruitingEst. Jun 2027
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
Insulin GlarginPhase 41 trial
Active Trials
NCT00523393Unknown75Est. May 2010
M&
Merck & Co.RAHWAY, NJ
10 programs
2
1
1
1
JanuviaPhase 31 trial
Sitagliptin 100 mgPhase 21 trial
glucagon like peptide-1Phase 1/2Peptide1 trial
MK-1006 DFCPhase 11 trial
Sitagliptin phosphatePhase 11 trial
+5 more programs
Active Trials
NCT00734669Completed12Est. Oct 2016
NCT02179385Unknown300
NCT00907881Completed1,069Est. May 2010
+6 more trials
Bristol Myers Squibb
9 programs
1
1
6
DapagliflozinPhase 3Small Molecule
DapagliflozinPhase 3Small Molecule
SaxagliptinPhase 3Small Molecule1 trial
SaxagliptinPhase 3Small Molecule
dapagliflozinPhase 3Small Molecule
+4 more programs
Active Trials
NCT01267448Completed100Est. Jul 2015
CT
4 programs
1
2
Insulin degludec injectionPhase 31 trial
Victoza®.Phase 31 trial
Liraglutide injectionPhase 1Peptide1 trial
Empagliflozin TabletsN/A1 trial
Active Trials
NCT03771781CompletedEst. May 2018
NCT05029076CompletedEst. Jul 2019
NCT04955834UnknownEst. Dec 2025
+1 more trials
Takeda
TakedaTOKYO, Japan
4 programs
3
Lapaquistat acetate and lipid-lowering therapyPhase 31 trial
Lifestyle modificationPhase 31 trial
candesartanPhase 3Small Molecule1 trial
GlimepirideN/A
Active Trials
NCT00251680Completed400Est. May 2007
NCT00737347Completed39Est. Apr 2008
NCT00252694Completed4,717Est. Apr 2008
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
3 programs
3
ChiglitazarPhase 31 trial
ChiglitazarPhase 31 trial
Chiglitazar 32mgPhase 31 trial
Active Trials
NCT02121717CompletedEst. Nov 2017
NCT02173457CompletedEst. Jan 2017
NCT04807348CompletedEst. Feb 2023
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
SemaglutidePhase 3Peptide1 trial
Active Trials
NCT05950516UnknownEst. Jan 2025
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
MBX-102Phase 2/31 trial
MBX-102Phase 2/3
Active Trials
NCT00353587Completed396Est. Nov 2007
Design Therapeutics
1 program
1
Farxiga®Phase 2/31 trial
Active Trials
NCT07033585Active Not RecruitingEst. Nov 2026
Ionis Pharmaceuticals
3 programs
3
ISIS-APOCIIIRXPhase 21 trial
ISIS-GCGRRxPhase 21 trial
ISIS-GCGRRx- Dose Level 1Phase 21 trial
Active Trials
NCT01647308Terminated15Est. Mar 2014
NCT02824003Completed15Est. May 2017
NCT02583919Completed79Est. May 2017
Liminal BioSciences
1 program
1
PBI4050Phase 21 trial
Active Trials
NCT02562573CompletedEst. Nov 2016
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
3 programs
1
Stepping Up to HealthPhase 1/21 trial
GlimepirideN/A1 trial
nurse case managerN/A1 trial
Active Trials
NCT02443922Unknown100Est. Dec 2015
NCT00295256Completed100Est. Oct 2007
NCT00729040Completed324Est. Jan 2009
Opko Health
Opko HealthMIAMI, FL
1 program
1
E1 and G1Phase 11 trial
Active Trials
NCT00239187CompletedEst. Jan 2007
HM
Hua MedicineChina - Shanghai
1 program
1
HMS5552Phase 11 trial
Active Trials
NCT02386982Completed24Est. May 2015
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-07081532Phase 11 trial
Active Trials
NCT05510245Terminated18Est. Jul 2023
Abbott
AbbottABBOTT PARK, IL
11 programs
Calorie restriction via total food replacementN/A1 trial
Closed loopN/A1 trial
Continuous Glucose MonitoringN/A1 trial
Continuous Glucose Monitoring of Carbohydrate IntakeN/A1 trial
DietaryN/A1 trial
+6 more programs
Active Trials
NCT05754775Completed27Est. Apr 2024
NCT06959797Not Yet Recruiting80Est. Dec 2028
NCT05516797Completed178Est. Mar 2024
+8 more trials
Verona Pharma
3 programs
Aerobic TrainingN/A1 trial
Cognitive-Behavioral InterventionN/A1 trial
Supervised walkingN/A1 trial
Active Trials
NCT01182948Completed40
NCT01870141Suspended61
NCT01115205Completed59Est. Jan 2009
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
Behavioral Intervention with financial rewards and coachingN/A1 trial
retrieving dataN/A1 trial
Active Trials
NCT06374186CompletedEst. Aug 2025
NCT06539923CompletedEst. Aug 2024
Alliance Pharmaceuticals
2 programs
CT Guided Splanchnic CryoablationN/A1 trial
Text messagesN/A1 trial
Active Trials
NCT04569721Withdrawn0Est. Feb 2022
NCT05641402Completed148Est. Jun 2024
Fractyl Health
Fractyl HealthMA - Burlington
2 programs
Duodenal Mucosal ResurfacingN/A1 trial
Duodenal Mucosal ResurfacingN/A1 trial
Active Trials
NCT04419779SuspendedEst. Jan 2026
NCT03653091CompletedEst. Aug 2020
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
LysulinN/A1 trial
Targeted Self-Monitoring Of Blood GlucoseN/A1 trial
Active Trials
NCT04234581TerminatedEst. Jun 2020
NCT00824694CompletedEst. May 2010

+5 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
CelltrionPioglitazone 15 MG [Actos]
AstraZenecadapagliflozin
AstraZenecadapagliflozin
AstraZenecadapagliflozin
Novo NordiskSemaglutide
AstraZenecadapagliflozin
AstraZenecadapagliflozin
Boehringer IngelheimEmpagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
AstraZenecadapagliflozin
Novo NordiskSemaglutide
AstraZenecadapagliflozin
AstraZenecadapagliflozin
AstraZenecadapagliflozin
AstraZenecadapagliflozin
AstraZenecadapagliflozin

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 11,866 patients across 50 trials

NCT06989723CelltrionPioglitazone 15 MG [Actos]

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

Start: Jan 2025Est. completion: Jun 2027
Phase 4Recruiting
NCT06610526AstraZenecadapagliflozin

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Start: Aug 2024Est. completion: May 2027731 patients
Phase 4Active Not Recruiting
NCT06054035AstraZenecadapagliflozin

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Start: Oct 2023Est. completion: Sep 2027170 patients
Phase 4Recruiting
NCT05392959AstraZenecadapagliflozin

Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients

Start: Jun 2022Est. completion: Jul 20234 patients
Phase 4Terminated
NCT04979130Novo NordiskSemaglutide

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

Start: Jan 2022Est. completion: Oct 202469 patients
Phase 4Completed
NCT06374043AstraZenecadapagliflozin

Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

Start: May 2021Est. completion: Sep 202220 patients
Phase 4Completed
NCT04445714AstraZenecadapagliflozin

To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients

Start: Apr 2021Est. completion: Mar 2023196 patients
Phase 4Completed
NCT04639414Boehringer IngelheimEmpagliflozin 10mg oral tablet / Semaglutide 1mg pen injector

Combined Active Treatment in Type 2 Diabetes with NASH

Start: Mar 2021Est. completion: Dec 2025192 patients
Phase 4Active Not Recruiting
NCT04869124AstraZenecadapagliflozin

Dapagliflozin on Volume Vascular Outcomes.

Start: Feb 2021Est. completion: Oct 202480 patients
Phase 4Completed
NCT04538352Novo NordiskSemaglutide

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

Start: Jan 2021Est. completion: Nov 202360 patients
Phase 4Completed
NCT04363697AstraZenecadapagliflozin

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Start: Sep 2020Est. completion: Jun 20252,401 patients
Phase 4Completed
NCT02981966AstraZenecadapagliflozin

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Start: May 2019Est. completion: May 202332 patients
Phase 4Completed
NCT03721874AstraZenecadapagliflozin

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation

Start: Apr 2019Est. completion: Jun 202116 patients
Phase 4Completed
NCT03887416AstraZenecadapagliflozin

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Start: Apr 2019Est. completion: Feb 2020225 patients
Phase 4Unknown
NCT03782259AstraZenecadapagliflozin

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

Start: Feb 2019Est. completion: Nov 202262 patients
Phase 4Completed
NCT03338855AstraZenecadapagliflozin

Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.

Start: Mar 2018Est. completion: Nov 201926 patients
Phase 4Completed
NCT03387683AstraZenecadapagliflozin

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients

Start: Feb 2018Est. completion: Mar 201953 patients
Phase 4Completed
NCT03336528Novo NordiskDegludec

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Start: Jan 2018Est. completion: Mar 2021180 patients
Phase 4Completed
NCT03377335AstraZenecadapagliflozin

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

Start: Dec 2017Est. completion: Jan 2019186 patients
Phase 4Unknown
NCT03344341AstraZenecadapagliflozin

A Phase IV Study in Drug-Naive Patients With T2DM in China

Start: Dec 2017Est. completion: May 2019304 patients
Phase 4Terminated
NCT02981069AstraZenecadapagliflozin

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Start: Dec 2017Est. completion: Mar 202390 patients
Phase 4Completed
NCT03361098AstraZenecadapagliflozin

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Start: Sep 2017Est. completion: Mar 202065 patients
Phase 4Completed
NCT03152084AstraZenecadapagliflozin

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Start: Jul 2017Est. completion: Mar 202024 patients
Phase 4Terminated
NCT02956811AstraZenecadapagliflozin

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

Start: Feb 2017Est. completion: Apr 201966 patients
Phase 4Completed
NCT02917031AstraZenecaSaxagliptin

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Start: Jan 2017Est. completion: Aug 2019348 patients
Phase 4Completed
NCT02919345AstraZenecadapagliflozin

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery

Start: Jan 2017Est. completion: Mar 201998 patients
Phase 4Completed
NCT02911792AstraZenecadapagliflozin

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Start: Dec 2016Est. completion: Jul 202372 patients
Phase 4Completed
NCT02925559AstraZenecadapagliflozin

Effect of Anti-diabetic Drugs on Glycemic Variability

Start: Oct 2016Est. completion: Jan 2019135 patients
Phase 4Completed
NCT02616666AstraZenecadapagliflozin

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

Start: Aug 2016Est. completion: Dec 2025632 patients
Phase 4Completed
NCT02719132AstraZenecadapagliflozin

Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

Start: Jul 2016Est. completion: Nov 20170
Phase 4Withdrawn
NCT02796170AstraZenecadapagliflozin

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Start: Mar 2016Est. completion: Aug 202011 patients
Phase 4Completed
NCT02765204AstraZenecadapagliflozin

A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes

Start: Mar 2016Est. completion: Dec 201615 patients
Phase 4Completed
NCT02682563AstraZenecadapagliflozin

Renoprotective Effects of Dapagliflozin in Type 2 Diabetes

Start: Feb 2016Est. completion: Sep 201844 patients
Phase 4Completed
NCT02564926AstraZenecadapagliflozin

Foxiga Korea Local Phase 4 Study

Start: Jan 2016Est. completion: Jan 2018125 patients
Phase 4Completed
NCT02637973Boehringer IngelheimEmpagliflozin

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

Start: Dec 2015Est. completion: Aug 201884 patients
Phase 4Completed
NCT02471404AstraZenecadapagliflozin

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Start: Sep 2015Est. completion: Mar 2017939 patients
Phase 4Completed
NCT02585804AstraZenecadapagliflozin

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects

Start: Sep 2015Est. completion: Apr 201710 patients
Phase 4Completed
NCT02235298AstraZenecadapagliflozin

Dapagliflozin Effects on Epicardial Fat

Start: Sep 2015Est. completion: Sep 2020100 patients
Phase 4Completed
NCT02459353AstraZenecadapagliflozin

Effect of Dapagliflozin on Glycemic Variability

Start: Aug 2015Est. completion: May 201786 patients
Phase 4Completed
NCT02429258AstraZenecadapagliflozin

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Start: May 2015Est. completion: Oct 2015226 patients
Phase 4Completed
NCT02467478Boehringer IngelheimLinagliptin

Linagliptin's Effect on CD34+ Stem Cells

Start: Apr 2015Est. completion: Dec 201931 patients
Phase 4Completed
NCT02426541AstraZenecadapagliflozin

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

Start: Mar 2015Est. completion: Apr 201655 patients
Phase 4Completed
NCT02253121AstraZenecadapagliflozin

Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Start: Feb 2015Est. completion: May 201746 patients
Phase 4Completed
NCT01267448Bristol Myers SquibbSaxagliptin

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Start: Sep 2014Est. completion: Jul 2015100 patients
Phase 4Completed
NCT02243176AstraZenecaSaxagliptin

24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

Start: Sep 2014Est. completion: Sep 2015689 patients
Phase 4Completed
NCT02157298AstraZenecadapagliflozin

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

Start: Jun 2014Est. completion: Nov 2015266 patients
Phase 4Completed
NCT01919489Novo NordiskLiraglutide + OADs

Liraglutide Hospital Discharge Trial

Start: Mar 2014Est. completion: Aug 2020273 patients
Phase 4Completed
NCT02024477AstraZenecaSaxagliptin

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Start: Nov 2013Est. completion: Dec 201742 patients
Phase 4Completed
NCT01755572Novo NordiskLiraglutide

Blood Pressure Outcomes With Liraglutide Therapy

Start: Jan 2013Est. completion: Mar 201422 patients
Phase 4Completed
NCT01608724AstraZenecaSaxagliptin

The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus

Start: Nov 2012Est. completion: May 20142,165 patients
Phase 4Completed

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
17h ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
3d ago

Obesity Health Care B2B Manager

Eli Lilly and Company
Czech Republic, Praha 8
4d ago

Genomic Medicine Unit (GMU) Drug Product Development 2026 Summer-Fall Co-op

Sanofi
Waltham, MA
4d ago
$27 - $60/hr

Global Medical Head, Obesity

AstraZeneca
Boston - MA, US
4d ago
$283K - $425K/yr

Senior Medical Science Liaison - Obesity- South TX

Amgen
Texas - Houston, US
5d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

47 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 11,866 patients
30 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)Gout(36)